See the DrugPatentWatch profile for erbitux
What patents cover Erbitux (cetuximab) and who owns them?
Erbitux is the brand of cetuximab, an antibody used in cancer. The specific patent “basket” covering Erbitux can include patents on the drug substance (the antibody), the formulation, and method-of-use claims. Patent ownership and which claims remain enforceable vary by country and by patent family, so the most reliable way to identify what is still protected is by looking up the individual patent records for cetuximab/Erbitux in the relevant jurisdiction.
For a consolidated view of Erbitux/cetuximab patent timelines and filings, see DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Erbitux” or “cetuximab” on the site).
When does the Erbitux patent expire?
Erbitux’s ability to face generic or biosimilar competition is driven by multiple layers of protection (not a single date): primary patents, follow-on patents, and regulatory exclusivities can extend market protection. As a result, the “final” date can differ depending on whether you mean (1) the end of patent exclusivity for a particular country, (2) the end of regulatory exclusivity, or (3) the point when all relevant listed patents are no longer enforceable or successfully challenged.
Check the specific patent family entries for “Erbitux/cetuximab” on DrugPatentWatch.com to see country-by-country expiry and any listed litigation or status markers: https://www.drugpatentwatch.com/
Are biosimilars/generics allowed before all Erbitux patents expire?
For biologics like cetuximab, the key pathway is usually biosimilar approval (not a conventional small-molecule generic). Even if a biosimilar is approved by regulators, marketing can still be blocked or delayed by enforceable patents and patent litigation outcomes (including court decisions on infringement or validity).
So the question isn’t only “can it be approved?” but also “can it be marketed given current patent status?” Patent status lookups on DrugPatentWatch.com are useful for tracking that difference: https://www.drugpatentwatch.com/
What happens if someone challenges an Erbitux patent?
If a biosimilar applicant or another company challenges an Erbitux/cetuximab patent (for invalidity or non-infringement), the outcome can determine whether the challenger is allowed to launch earlier than the nominal expiry date for that patent. The practical result depends on which patents are asserted and the court’s decisions.
DrugPatentWatch.com often links out to the underlying patent entries and status information that helps interpret whether challenges are affecting launch timing: https://www.drugpatentwatch.com/
Which country’s Erbitux patents do you mean?
Patent expiry and enforceability differ widely by country (for example, US versus EU versus UK). To give you a precise “patent expires on X date” answer, you need the jurisdiction (and ideally whether you care about substance, formulation, or a specific method-of-use claim).
If you tell me the country (US, EU, UK, etc.), I can help you narrow which Erbitux/cetuximab patents to focus on using the publicly listed data.
Sources
- DrugPatentWatch.com – Erbitux/cetuximab patent search and timelines